2024
Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems
Shin J, Xu Y, Chang A, Carrero J, Flaherty C, Mukhopadhyay A, Inker L, Blecker S, Horwitz L, Grams M. Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems. Journal Of The American College Of Cardiology 2024, 84: 683-693. PMID: 39142721, DOI: 10.1016/j.jacc.2024.05.057.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2Class 1A recommendationSodium-glucose cotransporter 2 inhibitor therapyChronic kidney diseaseU.S. health systemHealth systemInhibitor prescriptionHeart failurePrescription ratesInhibitor therapyInhibitor useSodium-glucose cotransporter 2 inhibitorsSodium-glucose cotransporter 2 inhibitor useOptum Labs Data WarehouseProportion of patientsSGLT2 inhibitor usePresence of diabetesRecurrent cardiovascular eventsAtherosclerotic cardiovascular diseaseCotransporter 2Analysis of U.S. dataSevere albuminuriaPrescription patternsCardiovascular eventsCommercial insuranceMeasuring Equity in Readmission as a Distinct Assessment of Hospital Performance
Nash K, Weerahandi H, Yu H, Venkatesh A, Holaday L, Herrin J, Lin Z, Horwitz L, Ross J, Bernheim S. Measuring Equity in Readmission as a Distinct Assessment of Hospital Performance. JAMA 2024, 331: 111-123. PMID: 38193960, PMCID: PMC10777266, DOI: 10.1001/jama.2023.24874.Peer-Reviewed Original ResearchConceptsBlack patientsPatient populationHospital characteristicsHospital-wide readmission measureDual-eligible patientsHospital patient populationCross-sectional studyMeasures of hospitalHealth care qualityPatient demographicsReadmission ratesClinical outcomesPatient raceEligible hospitalsReadmissionMAIN OUTCOMEReadmission measuresMedicare dataUS hospitalsHospitalCare qualityPatientsMedicaid ServicesOutcomesLower percentage
2020
Trends in COVID‐19 Risk‐Adjusted Mortality Rates
Horwitz LI, Jones SA, Cerfolio RJ, Francois F, Greco J, Rudy B, Petrilli CM. Trends in COVID‐19 Risk‐Adjusted Mortality Rates. Journal Of Hospital Medicine 2020, 16: 90-92. PMID: 33147129, DOI: 10.12788/jhm.3552.Peer-Reviewed Original ResearchConceptsHospital mortalityMortality rateHealth systemRisk-adjusted mortality ratesAdmission vital signsStandardized mortality ratioCoronavirus disease 2019Academic health systemPatient characteristicsClinical factorsMortality ratioDisease 2019High mortalityVital signsMortalityComorbiditiesCOVID-19Laboratory resultsEarlier reportsHospitalizationPatientsHospiceDemographicsFactors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study
Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, Tobin KA, Cerfolio RJ, Francois F, Horwitz LI. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. The BMJ 2020, 369: m1966. PMID: 32444366, PMCID: PMC7243801, DOI: 10.1136/bmj.m1966.Peer-Reviewed Original ResearchConceptsBody mass indexProspective cohort studyCritical illnessCoronavirus disease 2019Hospital admissionCohort studyHeart failureMale sexDisease 2019Hospice careAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionC-reactive protein levelsSingle academic medical centerAdmission oxygen saturationCoronavirus 2 infectionReactive protein levelsChronic kidney diseaseD-dimer levelsMarkers of inflammationAge 75 yearsSeverity of illnessStrong riskMultivariable logistic regression
2016
Association Between Hospital Penalty Status Under the Hospital Readmission Reduction Program and Readmission Rates for Target and Nontarget Conditions
Desai NR, Ross JS, Kwon JY, Herrin J, Dharmarajan K, Bernheim SM, Krumholz HM, Horwitz LI. Association Between Hospital Penalty Status Under the Hospital Readmission Reduction Program and Readmission Rates for Target and Nontarget Conditions. JAMA 2016, 316: 2647-2656. PMID: 28027367, PMCID: PMC5599851, DOI: 10.1001/jama.2016.18533.Peer-Reviewed Original ResearchConceptsHospital Readmissions Reduction ProgramAcute myocardial infarctionReadmission ratesReadmissions Reduction ProgramHeart failurePenalty statusNontarget conditionsMedicare feeMean readmission rateThirty-day riskRetrospective cohort studyUnplanned readmission rateReduction programsHRRP announcementHRRP implementationPenalized hospitalsCohort studyService patientsMyocardial infarctionMAIN OUTCOMEExcess readmissionsMedicare beneficiariesService beneficiariesHospitalPatientsQuasi-Experimental Evaluation of the Effectiveness of a Large-Scale Readmission Reduction Program
Jenq GY, Doyle MM, Belton BM, Herrin J, Horwitz LI. Quasi-Experimental Evaluation of the Effectiveness of a Large-Scale Readmission Reduction Program. JAMA Internal Medicine 2016, 176: 681. PMID: 27065180, DOI: 10.1001/jamainternmed.2016.0833.Peer-Reviewed Original ResearchConceptsDischarge patientsReadmissions Reduction ProgramControl populationReadmission ratesIntervention periodSame-hospital readmission ratesUrban academic medical centerTarget populationAdjusted readmission ratesOdds of readmissionHigh-risk patientsZip codesAdjusted admission ratesInterrupted time series analysisAcademic medical centerQuasi-experimental evaluationLogistic regression modelsReduction programsDischarge dispositionReadmission reduction effortsComparative interrupted time series analysisMedication reconciliationService patientsMean ageTransitional care